// App-Quantinova.ai

36 : Comparative analysis of overall survival in patients with HER2-amplified treatment-refractory metastatic colorectal cancer treated with pertuzumab plus trastuzumab in Mypathway and patients treated in the real-world.

Researchers

Presenter

  • Takuya Yoshimoto

Principal Investigators

  • Yusuke Narita

  • Miho Yuki

  • Takashi Asakawa

  • Satoe Kawakami

  • Craig Gower-Page

  • Irmarie Reyes-Rivera

  • Arisha Patel

  • Yoshiaki Nakamura

Medical Centers

  • Taiho Pharmaceutical Co., LTD., Tokyo, Japan

  • Roche Products Ltd., Welwyn Garden City, United Kingdom

  • F. Hoffmann-La Roche Ltd., Basel, Switzerland

  • Genentech, Inc., South San Francisico, CA

  • National Cancer Center, EPOC, Chiba, Japan

Locations

  • Japan

  • United Kingdom

  • Switzerland

  • United States

Companies

  • Chugai Pharmaceutica

  • Feng Chi Biotech Cor

  • Genentech, Inc.

Study Components

Therapeutic Area

  • Gastroenterology (GU)

  • Oncology (ONC)

Disease

  • Colorectal Cancer

Biomarkers

  • N/A

Drug/Treatment

  • Trastuzumab

  • Pertuzumab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • N/A

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved